US appeals court to weigh reviving cases over Tylenol and autism
A U.S. appeals court is expected to hear arguments on Monday from families seeking to revive their lawsuits over Tylenol, after the Trump administration publicly promoted their claims that the popular painkiller is linked to autism in children.
Judge to weigh if Texas AG can block Kenvue dividend over Tylenol
A Texas judge on Friday will consider state Attorney General Ken Paxton's bid to block Kenvue from paying a $398 million dividend to shareholders and from marketing Tylenol as safe for pregnant women.
Texas seeks to block Kenvue dividend amid Tylenol lawsuit
Texas Attorney General Ken Paxton on Thursday asked a state judge to block Kenvue from paying a nearly $400 million shareholder dividend this month, after suing the drugmaker for allegedly concealing risks to children from the use of Tylenol by pregnant women.
Sticker Shock: Why Kimberly-Clark's Sell-Off Is an Overreaction
On Nov. 3rd, Wall Street rendered a swift and brutal verdict on Kimberly-Clark's NASDAQ: KMB transformative acquisition of Kenvue NYSE: KVUE. While Kenvue's shares climbed over 12%, Kimberly-Clark's stock price dropped more than 14% to a new 52-week low, wiping out approximately $5.8 billion in market value in a single trading session.
S&P 500 Gains & Losses Today: Amazon Stock Jumps After OpenAI Deal; Kimberly-Clark Acquires Kenvue
A linkup with an artificial intelligence player helped power shares of a top cloud-computing services company higher Monday, while an acquisition in the consumer goods space sent the two stocks on divergent paths.
KVUE stock price: Kenvue soars 19% today, Kimberly-Clark deal offers a win after Trump Tylenol drama
It's been a tough few weeks for the consumer health company Kenvue, after President Trump publicly spread unproven claims about Tylenol, one of its core subsidiary brands. Today, though, it seems like there might finally be some good news for Kenvue.
Why Tylenol maker stock is popping despite Trump's autism warning
Kenvue (NYSE: KVUE) shares surged Monday, climbing by double digits as investors cheered news that consumer goods giant Kimberly-Clark (NASDAQ: KMB) plans to acquire the Tylenol maker
Top Stock Movers Now: Amazon, Kenvue, Kimberly-Clark, Beyond Meat, and More
Major U.S. equities indexes were mixed Monday afternoon, as tech stocks gained but most other sectors declined. The S&P 500 and Nasdaq rose, while the Dow fell.
Kimberly-Clark Is Buying Tylenol Maker Kenvue for Nearly $49B. Here's What You Need to Know
Kenvue (KVUE) shares skyrocketed in early trading Monday after Kleenex and Cottonelle maker Kimberly-Clark (KMB) said it's buying the Tylenol maker in a $48.7 billion deal.
Kimberly-Clark to acquire Tylenol-maker Kenvue in $48.7B deal
Kimberly-Clark Corp (NYSE:KMB, ETR:KMY) announced it will acquire Kenvue (NYSE:KVUE), the maker of Tylenol and other consumer health products, in a cash and stock transaction valued at approximately $48.7 billion. Under the agreement, Kenvue shareholders will receive $3.50 per share in cash plus 0.14625 Kimberly-Clark shares for each Kenvue share, totaling $21.01 per share based on Kimberly-Clark's recent stock price.
Tylenol Maker Eyes Best Day Ever on Kimberly-Clark Deal
Tylenol maker and former Johnson & Johnson (JNJ) spinoff Kenvue Inc (NYSE:KVUE) is 16.7% higher to trade at $16.74, after Kimberly-Clark Corp (NASDAQ:KMB) agreed to purchase the pharma name for $48.70 billion in cash and stock.
Activist Investors in Kenvue Faced Big Losses. Kimberly-Clark Saved the Day.
D.E. Shaw, one of the Tylenol-maker's largest shareholders, stood to lose over $200 million but is now expected to break even on its bet.
